Anixa Biosciences, Inc.
ANIX · NASDAQ
Market closed$3.40$0.080000 (+2.41%)After hours $3.47 · +2.06%
Key statistics
Previous close$3.32
Open$3.44
Day high$3.55
Day low$3.29
52-week high$5.46
52-week low$2.32
Market cap115.68M
Volume174.51K
Average volume188.64K
P/E ratio-10.97
Forward P/E—
EPS-0.31
Dividend yield0.00%
Market context
Why it moved
ANIX edged higher on light but steady buying interest, likely supported by technical support levels near $3.20 and bullish momentum signals, as the stock bounced within its short-term rising trend without a clear specific catalyst identified in available news.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · July 16, 2026Director Lewis Titterton buys more Anixa Biosciences Inc (ANIX) stockPR Newswire · July 14, 2026Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine TechnologyStock Titan · July 6, 2026Anixa’s ovarian cancer CAR-T reaches highest dose, no toxicities seenStock Titan · June 29, 2026Anixa gets first Korean patent for breast cancer vaccinePR Newswire · June 26, 2026Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy SymposiumPR Newswire · June 11, 2026Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy SymposiumStock Titan · June 1, 2026Ovarian cancer vaccine targeting 'retired' protein wins Canada patent backingSimply Wall Street · March 25, 2026We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate Benzinga · July 14, 2026Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology Mt Newswire · July 6, 2026Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial Benzinga · July 6, 2026Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer Mt Newswire · June 29, 2026Anixa Biosciences Granted Korean Patent for Breast Cancer Vaccine Benzinga · June 29, 2026Anixa Biosciences Receives Patent From South Korea's Ministry Of Intellectual Property For Its Breast Cancer Vaccine Technology Benzinga · June 26, 2026Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants Benzinga · June 10, 2026Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate Mt Newswire · June 1, 2026Anixa Biosciences Says Canadian IP Office Issues Notice of Allowance for Patent Covering Ovarian Cancer Vaccine Technology